## Exercises KJ 5230: Nov. 10<sup>th</sup> – 2004

**1.** The compounds shown below has antibacterial activity. Resistance to the compounds was shown to be the result of a single-point mutation of an lysine residue to an aspartate residue in the active site of the target bacterial enzyme. Suggest a structure that may be active against the resistant strain.



**2.** Explain how you may determine if a compound is a competitive or non-competitive inhibitor of an enzyme.

**3.** Which of the hypothetic metabolites are phase I and phase II?. Name reactions and co-actors required. (no mechanisms)



a) Compounds **A-D** are used to treat infections. What calsses of drugs do they belong to. Explain how you can distinguish between the drug classes of **B** and **D**.



b) **E** is more stable in acidic media than **A**. Show (incl mecanisms) how **A** can be transformed to the intermediate **F** in acidic media and use this mecanism to explain why **E** is more stabile



c) A is naturally occuring, but G and H are semisynthetic analogs. Explain why these modifications have been done.

d) I is used in combination with drugs like A. Explain why and show mechanism of action for I.

e) **D** has low stability in acidic media. Explain why, and discuss synthetic modifications that would increase stability.

f) Discuss stability (hydrolytic and enzymatic) of cephalosposines and compare with pennicilines

- 5.
- a) Why should not tetracyclines be taken with milk?
- b) Compare stability of doxycyclin and oxytetracyclin. (include mechanisms for reactions that may occur in aqueous media at various pH)